MetaCap

Senti Biosciences (SNTI) vs VivoSim Labs (VIVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

VivoSim Labs is the larger company by market cap ($5.3 million vs $4.6 million), about 1.2 times the size. VivoSim Labs converts more of its revenue into profit, with a net margin of -10567.2% versus -279263.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SNTI+436.36%VIVS+36.19%
+786%+336%-115%
Oct 7, 20261 yearNov 20, 2026
SNTI+462.98%VIVS+44.81%
+489%+204%-81%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SNTI versus VIVS key metrics
MetricSNTIVIVS
Share price$1.77$0.2608
Market cap$4.60M$5.29M
1-day change-36.56%-10.53%
YTD return+70.19%—
1-year return-8.76%—
5-year return-98.23%—
EPS (TTM)$-46.20$-3.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$22.00K$131.00K
Revenue growth (YoY)—-9.03%
Net income (latest FY)$-61.44M$-13.84M
Gross margin—100.00%
Operating margin-312631.82%-8768.70%
Net margin-279263.64%-10567.18%
52-week high$95.04$3.40
52-week low$1.71$0.12
Distance from 52-week high-98.14%-92.33%
Analyst consensusnone—
Avg. price target upside+662.71%—
Average volume108.98K15.96M
Shares outstanding2.60M20.28M
Employees3915
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VivoSim Labs is more profitable, keeping -10567.2 cents of every revenue dollar as net income versus -279263.6 cents for Senti Biosciences.

About Senti Biosciences

SNTI stock →

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About VivoSim Labs

VIVS stock →

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees

SNTI vs VIVS FAQ

Which is bigger, Senti Biosciences or VivoSim Labs?

VivoSim Labs (VIVS) is larger, with a market capitalization of $5.29M compared with $4.60M for Senti Biosciences (SNTI).

Are Senti Biosciences and VivoSim Labs in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons